All In Biotech

Drug Trial Radar · NCT04425018

MARGetuximab Or Trastuzumab (MARGOT)

MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast Cancer

Last checked: Nov 20, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 174 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

174

Actual

Start

Jul 13, 2020

Primary completion

Oct 24, 2024

Study completion Jul 1, 2027

Sponsor

Lead sponsor
Dana-Farber Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
MacroGenics; Translational Breast Cancer Research Consortium
First posted
Jun 11, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine how well participants with stage II-III HER2-positive breast cancer respond to pre-operative treatment using one of two different combinations of drugs. Drugs and Combinations used: * Paclitaxel, Pertzumab and Margetuximab (Margenza) * Paclitaxel, Pertzumab and Trastuzumab (Herceptin)

Conditions

  • Breast Cancer
  • Stage II Breast Cancer
  • Stage III Breast Cancer
  • HER2-positive Breast Cancer

Interventions

  • PaclitaxelDrug

    Pre-determined dose administered via IV, Day 1,8,15 of each cycle 4 study cycles, or 12 weeks.

  • PertuzumabDrug

    Pre-determined dose administered via IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.

  • MargetuximabDrug

    Pre-determined dose administered by IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.

  • TrastuzumabDrug

    Pre-determined dose administered via IV Day 1 of each 21- day cycle for 4 study cycles, or 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathologic Complete Response (pCR)Time frame: 12 weeks

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Dana-Farber Brigham Cancer Center - Foxborough

    Foxborough, Massachusetts

  • Dana-Farber at Milford

    Milford, Massachusetts

  • Dana-Farber at South Shore Hospital

    Weymouth, Massachusetts

  • Montefiore Medical Center

    The Bronx, New York

  • UPMC Hillman Cancer Center - Arnold Palmer at Mountain View

    Greensburg, Pennsylvania

  • UPMC Hillman Cancer Center - Arnold Palmer at Norwin

    Irwin, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Baylor College of Medicine Medical Center

    Houston, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • University of Washington Fred Hutchinson Cancer Care

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.